Biomedical 13th Five-Year Plan to Introduce in the Second Half of the Year
Medical Network July 4th The reporter recently learned from the authoritative channel that the “13th Five-Year Plan” for biomedicine has been basically completed. According to the relevant work process, this plan will be officially introduced in the second half of this year. According to the plan, during the “Thirteenth Five-Year Plan” period, China's biomedical industry will focus on the development of a number of innovative pharmaceutical products such as major disease chemical drugs, biotechnology drugs, new vaccines, and new cell therapy preparations, as well as major medical technologies such as bio 3D printing technology.
According to the plan, anti-tumor, anti-depression, diabetes, kidney disease, cardiovascular and cerebrovascular diseases and other drugs will be the key drugs for the development during the 13th Five-Year Plan period; protein and peptide drugs and new cell preparations with great application prospects in clinical practice. Biomedical preparations will also be given priority; in addition, cutting-edge biomedical technologies such as bio-3D printing, macromolecular drugs, stem cells, and genes will also be developed in the next five years.
In addition, the plan also proposes to speed up the imitation of patent expired drugs. For the prevention and treatment of major diseases or sudden outbreaks, the combination of imitation and innovation, system integration, the development of 20 to 30 clinically demanding drug categories, and effectively solve the industrialization problem, to meet the urgent needs of clinical drugs, to 2020 international patents More than 90% of the important drugs that are due are used for imitation production.
It is worth noting that in addition to the detailed deployment of the research and development and technological development of the pharmaceutical products during the 13th Five-Year Plan period, the 13th Five-Year Plan of Biomedicine has also set new development goals for the entire biomedical industry, namely to further promote the entire The international development of the industry.
According to the plan, by 2020, a large number of biopharmaceutical enterprises should be promoted to achieve drug quality standards and systems in line with international standards. At least 100 pharmaceutical preparation companies have obtained certifications from the United States, Europe, Japan and other developed countries and WHO, and have achieved drug exports; International drug standards, development and promotion of 10 to 20 chemical drugs and high-end preparations, 3 to 5 new Chinese medicines, 3 to 5 new biotechnology drugs in the developed countries of Europe and the United States to complete drug registration, and accelerate their entry into the international market.
The plan also proposes to promote three to five well-established colleges and universities and pharmaceutical companies to jointly establish a large-scale pharmaceutical R&D base with high technology and R&D capabilities by 2020, and establish a national-level transformation science center and collaborative innovation center to break through. 10 to 20 major core technologies, initially establishing a national drug innovation system and innovation team, and bringing China's pharmaceutical industry system to the international advanced level, and promoting some key pharmaceutical companies to gain a foothold in the international market, striving to achieve an average international sales revenue of over 100 The level of 100 million yuan.
The National Manufacturing Powerful Country Construction Strategy Advisory Committee introduced to the Economic Information Daily that the development of the biomedical industry is of great significance. On the one hand, China's biomedical market is huge. At present, China is the second largest pharmaceutical consumer market in the world. In 2014, the pure sales of China's pharmaceutical market has exceeded 1.5 trillion yuan. At present, China has entered an aging society. The population over 65 years old has more than 120 million people. The rapid growth of medical demand will put forward new requirements for the future development of China's biomedical industry. On the other hand, although China's biomedical industry is huge, it will be fully in 2014. Industrial sales are close to 2.5 trillion yuan, but the independent research and development of China's drugs is still very weak, drug production is mainly based on imitation, less original drugs, and biomedical key technologies are also far from the international level. Therefore, cultivating and developing the bio-pharmaceutical industry and promoting the whole industry to participate in international competition will become the key to improving the overall development level and competitiveness of China's bio-pharmaceutical industry.
In order to achieve the above-mentioned planning goals during the 13th Five-Year Plan period, the plan also proposed a number of strategic support and safeguard measures. These include: GCPs in accordance with international standards for drug clinical trials (GCP) and non-clinical research quality management practices (GLP), establishing or standardizing key front-end and clinical evaluation platforms for new drugs at the international frontier; optimizing and improving new drugs Priority review and rapid approval policies, strengthen the expansion of the inspection and inspection personnel team; refine the implementation of the State Council's "Opinions on reforming the drug medical device review and approval system" to ensure the approval of new drugs.
China Merchants Securities and other brokerage research reports pointed out that the bio-pharmaceutical industry, as one of the seven strategic emerging industries identified by China, has great practical and economic significance. On the one hand, accelerating the development of the bio-pharmaceutical industry will further meet the growing health and health service needs of our people; on the other hand, as an important industry, the bio-pharmaceutical sector is closely related to the basic manufacturing sectors such as the chemical industry, and the overall development of the bio-pharmaceutical industry is enhanced. The level has also greatly promoted the transformation and upgrading of traditional industries such as promoting upstream and downstream industries and driving chemicals.